March 11, 2022
A group of researchers in Japan has investigated the in-vitro efficacy of COVID-19 antibody and antiviral therapies against the BA.2 Omicron subvariant, which is expected to be a predominant coronavirus strain in Japan in the coming weeks. According to their...read more